TD Cowen Forecasts Strong Price Appreciation for Clorox (NYSE:CLX) Stock

Clorox (NYSE:CLX) had its price objective hoisted by TD Cowen from $108.00 to $111.00 in a report issued on Wednesday,MarketScreener reports. The brokerage currently has a “hold” rating on the stock. TD Cowen’s price target indicates a potential downside of 5.96% from the company’s previous close.

Several other research analysts have also commented on the stock. The Goldman Sachs Group dropped their price target on shares of Clorox from $110.00 to $94.00 and set a “sell” rating on the stock in a research note on Wednesday, January 7th. Rothschild & Co Redburn lowered their target price on shares of Clorox from $120.00 to $115.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 5th. Wall Street Zen cut Clorox from a “hold” rating to a “sell” rating in a research report on Saturday, January 24th. Royal Bank Of Canada set a $132.00 price objective on Clorox in a report on Wednesday. Finally, Zacks Research upgraded Clorox from a “strong sell” rating to a “hold” rating in a report on Wednesday, November 26th. One equities research analyst has rated the stock with a Buy rating, eleven have assigned a Hold rating and four have given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Reduce” and a consensus price target of $117.93.

Clorox Stock Up 0.2%

CLX traded up $0.26 during trading on Wednesday, reaching $118.03. 1,362,834 shares of the stock traded hands, compared to its average volume of 2,393,551. The stock’s 50-day simple moving average is $105.39 and its two-hundred day simple moving average is $113.99. The company has a debt-to-equity ratio of 18.01, a current ratio of 0.76 and a quick ratio of 0.50. Clorox has a fifty-two week low of $96.66 and a fifty-two week high of $159.04. The stock has a market cap of $14.40 billion, a price-to-earnings ratio of 19.33, a price-to-earnings-growth ratio of 0.57 and a beta of 0.59.

Clorox (NYSE:CLX) last announced its quarterly earnings results on Tuesday, February 3rd. The company reported $1.39 EPS for the quarter, missing the consensus estimate of $1.43 by ($0.04). Clorox had a net margin of 11.17% and a return on equity of 299.67%. The firm had revenue of $1.67 billion during the quarter, compared to the consensus estimate of $1.64 billion. During the same period in the previous year, the firm posted $1.55 EPS. The company’s quarterly revenue was down .8% compared to the same quarter last year. As a group, equities research analysts expect that Clorox will post 7.15 EPS for the current year.

Insiders Place Their Bets

In other Clorox news, Director Pierre R. Breber acquired 4,000 shares of the company’s stock in a transaction dated Friday, November 21st. The stock was bought at an average price of $104.13 per share, for a total transaction of $416,520.00. Following the purchase, the director owned 13,000 shares in the company, valued at $1,353,690. This represents a 44.44% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.63% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Nomura Asset Management Co. Ltd. lifted its position in shares of Clorox by 9.0% during the second quarter. Nomura Asset Management Co. Ltd. now owns 335,514 shares of the company’s stock valued at $40,285,000 after purchasing an additional 27,639 shares in the last quarter. Hudson Bay Capital Management LP purchased a new position in shares of Clorox in the second quarter valued at $8,568,000. Vanguard Personalized Indexing Management LLC raised its position in shares of Clorox by 64.2% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 25,732 shares of the company’s stock valued at $3,173,000 after buying an additional 10,065 shares in the last quarter. Vise Technologies Inc. bought a new stake in Clorox in the 2nd quarter worth approximately $328,000. Finally, Brookstone Capital Management boosted its stake in Clorox by 1,395.4% in the third quarter. Brookstone Capital Management now owns 94,332 shares of the company’s stock worth $11,631,000 after buying an additional 88,024 shares in the last quarter. Institutional investors and hedge funds own 78.53% of the company’s stock.

Clorox News Summary

Here are the key news stories impacting Clorox this week:

• Positive Sentiment: Morgan Stanley raised its price target to $136 (equal‑weight), implying meaningful upside from current levels — a clear bullish signal from a large shop. Morgan Stanley raises CLX PT to $136
• Positive Sentiment: Clorox slightly beat revenue expectations for Q2 ($1.67B vs. ~$1.64B) and reaffirmed its 2026 outlook, which can temper downside after the quarter. Clorox Posts Mixed Q2 Results, Reaffirms 2026 Outlook
• Positive Sentiment: Jefferies remains a buy on CLX with a $151 target (still a sizable upside), signaling some Wall Street conviction in longer‑term recovery despite the miss. Jefferies maintains buy on CLX
• Neutral Sentiment: Management is weighing a potential GOJO acquisition while finishing ERP integration; the deal could be strategic but creates short‑term execution and capital allocation uncertainty. Clorox Weighs GOJO Deal And ERP Finish Against Softer Earnings
• Neutral Sentiment: CLX will present at the CAGNY conference (Feb. 19); investor access could provide more clarity on margins, integration progress and M&A plans. Clorox to Present at 2026 CAGNY Conference
• Neutral Sentiment: JPMorgan nudged its target to $117 (neutral), reflecting mixed analyst views that keep near‑term expectations subdued. JPMorgan adjusts CLX PT to $117
• Negative Sentiment: Q2 EPS missed consensus (reported $1.39 vs. ~$1.43) and EPS/organic sales declined year‑over‑year; investors are focused on margin pressure and shoppers trading down to cheaper alternatives. Clorox misses quarterly profit estimates
• Negative Sentiment: Analysts cut targets or issued cautious ratings (Deutsche Bank to $112, Evercore to $115/underperform), reflecting concern about inventory resets, ERP costs and near‑term profit squeeze. Deutsche Bank lowers CLX PT
• Negative Sentiment: Market reaction: shares slipped after the earnings miss and commentary about integration and inventory reset pressures — near‑term downside risk remains if margins don’t stabilize. CLX Q2 Earnings Miss

About Clorox

The Clorox Company is a leading manufacturer and marketer of consumer and professional products designed to help people care for their homes and live healthy, sustainable lives. Its portfolio spans cleaning and household products, food and beverages, water filtration systems and cat litter, serving both retail and institutional customers. The company’s flagship bleach and disinfecting products are well known in the United States and many international markets, where they help prevent the spread of germs in homes, hospitals, schools and businesses.

Clorox’s diverse brand lineup includes liquid bleach and surface cleaners, eco-friendly cleaning tools, food preservation and preparation items, charcoal grills and briquettes, specialty foods and beverages, pet care products and personal care lines.